MRVI (Maravai LifeSciences Holdings, Inc.) Stock Financials & Earnings

MRVIMaravai LifeSciences Holdings, Inc.

Mkt Cap$999M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$186M

Net Income (TTM)-$131M

EPS (TTM)-$0.91

Free Cash Flow (TTM)-$71M

Gross Margin18.0%

Op. Margin-3.6%

Net Margin-70.4%

FCF Margin-38.1%

P/S Ratio (TTM)5.4x

P/E Ratio (TTM)—

YoY Rev Growth-28.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$79M	$45M	$3M
Q2 23	$69M	$26M	-$12M
Q3 23	$67M	$30M	-$15M
Q4 23	$74M	$39M	-$7M
Q1 24	$64M	$26M	-$19M
Q2 24	$73M	$35M	-$10M
Q3 24	$65M	$28M	-$169M
Q4 24	$56M	$19M	-$38M
Q1 25	$47M	$8M	-$49M
Q2 25	$47M	$8M	-$66M
Q3 25	$42M	$6M	$115M
Q4 25	$50M	$12M	-$7M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Biologics Safety Testing Segment	Nucleic Acid Production Segment
Q1 23	$18M	$61M
Q2 23	$16M	$53M
Q3 23	$16M	$51M
Q4 23	$15M	$59M
Q1 24	$18M	$46M
Q2 24	$15M	$58M
Q3 24	$15M	$50M
Q1 25	$18M	$29M
Q2 25	$16M	$31M
Q3 25	$16M	$25M

Revenue by Geography

Quarter	Asia Pacific	Emea	Latin And Central America	North America
Q3 23	$25M	$8M	$105K	$35M
Q1 24	$21M	$9M	$307K	$33M
Q2 24	$23M	$18M	$120K	$32M
Q3 24	$23M	$7M	$125K	$35M
Q1 25	$11M	$7M	$146K	$29M
Q2 25	$8M	$8M	$205K	$31M
Q3 25	$8M	$8M	$296K	$25M
Q4 25	$14M	$8M	$324K	$27M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$628M	$0	$628M
Q2 23	$580M	$0	$580M
Q3 23	$580M	$0	$580M
Q4 23	$575M	$0	$575M
Q1 24	$562M	$0	$562M
Q2 24	$573M	$0	$573M
Q3 24	$578M	$0	$578M
Q4 24	$322M	$0	$322M
Q1 25	$285M	$0	$285M
Q2 25	$270M	$0	$270M
Q3 25	$244M	$0	$244M
Q4 25	$217M	$0	$217M

Shares Outstanding

Revenue Per Employee

Revenue / Employee